Portal de investigação
Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Almeida-Nunes, DL
- Silva, JPN
- Nunes, M
- Silva, PMA
- Silvestre, R
- Bousbaa, H
- Ricardo, S
Unidades de investigação
Abstract
Ovarian cancer (OC) remains one of the leading causes of cancer-related mortality among women. Targeting the insulin-like growth factor 1 (IGF-1) signaling pathway has emerged as a promising therapeutic strategy. Linsitinib, an IGF-1 receptor (IGF-1R) inhibitor, has shown potential in disrupting this pathway. Additionally, metformin, commonly used in the treatment of type 2 diabetes, has been studied for its anti-cancer properties due to its ability to inhibit metabolic pathways that intersect with IGF-1 signaling, making it a candidate for combination therapy in cancer treatments. This study explores the anti-cancer effects of linsitinib and metformin on OVCAR3 cells by the suppression of the IGF-1 signaling pathway by siRNA-mediated IGF-1 gene silencing. The goal is to evaluate their efficacy as therapeutic agents and to emphasize the critical role of this pathway in OC cell proliferation. Cellular viability was evaluated by resazurin-based assay, and apoptosis was assessed by flux cytometry. The results of this study indicate that the combination of linsitinib and metformin exhibits an antagonistic effect (obtained by SynergyFinder 2.0 Software), reducing their anti-neoplastic efficacy in OC cell lines. Statistical analyses were performed using ordinary one-way or two-way ANOVA, followed by Tukey's or & Scaron;& iacute;d & aacute;k's multiple comparison tests. While linsitinib shows promise as a therapeutic option for OC, further research is needed to identify agents that could synergize with it to enhance its therapeutic efficacy, like the combination with standard chemotherapy in OC (carboplatin and paclitaxel).
Dados da publicação
- ISSN/ISSNe:
- 1661-6596, 1661-6596
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
International Journal of Molecular Sciences Multidisciplinary Digital Publishing Institute (MDPI)
Documentos
- Não há documentos
Filiações
Keywords
- ovarian cancer; linsitinib; IGF-1 signaling pathway; metformin; cell viability; apoptosis
Campos de estudo
Financiamento
Proyectos asociados
Clinical and forensic aspects of ibogaine
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico (Forensic) . 2020
Pharmacokinetics and Pharmacodynamics of Dextromethorphan: Clinical and Forensic Aspects
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2020
Clinical and Forensic signs resulting from exposure to toxic elements
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2022
Inhalant Abuse: A New Psychoactive Trend With Clinical And Forensic Implications
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2022
Pharmacokinetics and pharmacodynamics of buprenorphine: Relevant clinical and forensic aspects
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2022
Clinical and forensic aspects of bromism: manifestations and treatment
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2022
Clinical and Forensic Aspects of Jellyfish Stings
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2022
Technical aspects related to harmonized procedures for photographic registration in forensic autopisies
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2023
Toxicological mechanisms of tramadol and tapentadol: biomedical and forensic insights from in vivo studies.
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2022
Clinical and Forensic Aspects of Pharmacobezoars
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2020
Research into toxicological mechanisms of tramadol and tapentadol: clinical and forensic aspects.
Investigador Principal: Ricardo Jorge Dinis Oliveira
Estudo Clínico Académico . 2019
Citar a publicação
Almeida DL,Silva JPN,Nunes M,Silva P,Silvestre R,Dinis RJ,Bousbaa H,Ricardo S. Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines. Int. J. Mol. Sci. 2024. 25. (22):11935. IF:5,600. (1).
